CureMatch Articles & News
CureMatch has been featured in GenomeWeb’s recent in-depth article, “CureMatch Building Genomic Therapy-Matching Business Focused on Drug Combinations.” The article discusses CureMatch’s innovative product, which guides oncologists in the selection of cancer drugs customized for individual patients based on genomics. The product considers more than 4.5 million different cancer treatment options, including combinations of drugs. […]
Cancer comes with its own terminology—hopefully over the course of a series of blog posts we will clarify some of these terms and concepts. Because, after all, how can one make an informed decision about cancer treatment options if one doesn’t understand the disease and the cancer mutations involved? What Is Cancer? First of all, […]
Despite the fact that pediatric cancer death rates have decreased and survival rates increased over the past decades as a result of major advances in cancer treatment, cancer continues to remain a leading cause of death among children. According to the National Cancer Institute, in 2017, an estimate of 10,270 new cases of pediatric cancer […]
New cancer research titled “BRAF Mutation as a Novel Driver of Eosinophilic Cystitis” was recently published in the Cancer Biology & Therapy Journal and includes work by CureMatch Co-Founders Igor F. Tsigelny, Ph.D. and Razelle Kurzrock, M.D. along with colleagues from the San Diego Supercomputer Center and UCSD Moores Cancer Center. This article highlights the role of a specific molecular mutation in eosinophilic cystitis, a rare inflammatory bladder condition. Genetic markers such as BRAF I463T provide some of the best indicators to recommend personalized treatments and improve survival rates.
“You have pancreatic cancer” – Shock, sadness, worry, and fear are all emotions that cancer patients may feel when hearing such devastating prognosis. To make matters worse, pancreatic cancer is expected to become the second leading cause of cancer deaths in the US by 2020. Stage IV pancreatic cancer patients have an average survival rate of only 1.5% after 5 years. Pancreatic cancer is also difficult to detect because there are no signs or symptoms in early stages of the cancer. Additionally, early symptoms often share similarities with other types of illnesses resulting in either a wrong diagnosis or catching the cancer at an advanced stage. But there is hope...